TWI805630B - 醫藥組合物 - Google Patents

醫藥組合物 Download PDF

Info

Publication number
TWI805630B
TWI805630B TW107137033A TW107137033A TWI805630B TW I805630 B TWI805630 B TW I805630B TW 107137033 A TW107137033 A TW 107137033A TW 107137033 A TW107137033 A TW 107137033A TW I805630 B TWI805630 B TW I805630B
Authority
TW
Taiwan
Prior art keywords
obinutuzumab
cycle
hour
administration
rate
Prior art date
Application number
TW107137033A
Other languages
English (en)
Chinese (zh)
Other versions
TW201922284A (zh
Inventor
麥可 溫格
梅爾達德 孟巴薛
錦瑜 林
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI805630(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW201922284A publication Critical patent/TW201922284A/zh
Application granted granted Critical
Publication of TWI805630B publication Critical patent/TWI805630B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
TW107137033A 2017-10-19 2018-10-19 醫藥組合物 TWI805630B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
US62/574,297 2017-10-19

Publications (2)

Publication Number Publication Date
TW201922284A TW201922284A (zh) 2019-06-16
TWI805630B true TWI805630B (zh) 2023-06-21

Family

ID=64362606

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107137033A TWI805630B (zh) 2017-10-19 2018-10-19 醫藥組合物
TW112120572A TWI828593B (zh) 2017-10-19 2018-10-19 醫藥組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112120572A TWI828593B (zh) 2017-10-19 2018-10-19 醫藥組合物

Country Status (14)

Country Link
US (2) US12129304B2 (OSRAM)
EP (2) EP4520347A3 (OSRAM)
JP (2) JP6860652B2 (OSRAM)
KR (2) KR20240157135A (OSRAM)
CN (2) CN120983618A (OSRAM)
AU (2) AU2018303836B2 (OSRAM)
BR (1) BR112020007731A2 (OSRAM)
CA (1) CA3079374A1 (OSRAM)
ES (1) ES3005784T3 (OSRAM)
IL (2) IL321935A (OSRAM)
MX (2) MX419643B (OSRAM)
PL (1) PL3697818T3 (OSRAM)
TW (2) TWI805630B (OSRAM)
WO (1) WO2019017499A2 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805630B (zh) * 2017-10-19 2023-06-21 瑞士商赫孚孟拉羅股份公司 醫藥組合物
KR20220079858A (ko) * 2019-10-04 2022-06-14 추가이 세이야쿠 가부시키가이샤 오비누투주맙 내성 cd20 양성 암의 세포의 증식을 억제하는 제, 및 그에 관련된 의약 조성물, 의약, 제조, 세포의 증식을 억제하는 방법, 치료 방법, ii형 항cd20 항체, 화합물, 그들의 조합, 증강제 및 유도제
WO2023042679A1 (ja) 2021-09-17 2023-03-23 キヤノン株式会社 送電装置および受電装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024228A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416262B1 (pt) 2003-11-05 2022-04-12 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
NZ585516A (en) 2007-12-21 2012-07-27 Hoffmann La Roche Anti-cd20 antibody formulation
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
WO2019017449A1 (ja) 2017-07-21 2019-01-24 横浜ゴム株式会社 空気入りタイヤ
TWI805630B (zh) * 2017-10-19 2023-06-21 瑞士商赫孚孟拉羅股份公司 醫藥組合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024228A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Kensei Tobinai A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies Adv The 34 2017 324-356 *

Also Published As

Publication number Publication date
IL273909B1 (en) 2025-08-01
CA3079374A1 (en) 2019-01-24
TW201922284A (zh) 2019-06-16
AU2025205481A1 (en) 2025-08-07
US20200299398A1 (en) 2020-09-24
EP4520347A2 (en) 2025-03-12
JP2021152002A (ja) 2021-09-30
AU2018303836B2 (en) 2025-04-17
PL3697818T3 (pl) 2025-03-24
AU2018303836A1 (en) 2020-05-14
IL273909A (en) 2020-05-31
TWI828593B (zh) 2024-01-01
JP6860652B2 (ja) 2021-04-21
ES3005784T3 (en) 2025-03-17
EP3697818B1 (en) 2024-11-27
IL321935A (en) 2025-09-01
US20250026847A1 (en) 2025-01-23
MX2024009217A (es) 2024-11-08
MX2020003418A (es) 2020-07-20
CN111212854A (zh) 2020-05-29
JP7370357B2 (ja) 2023-10-27
WO2019017499A3 (en) 2019-02-21
EP4520347A3 (en) 2025-06-04
TW202342099A (zh) 2023-11-01
IL273909B2 (en) 2025-12-01
CN120983618A (zh) 2025-11-21
JP2019528282A (ja) 2019-10-10
EP3697818A2 (en) 2020-08-26
KR20200067196A (ko) 2020-06-11
KR102766089B1 (ko) 2025-02-13
KR20240157135A (ko) 2024-10-31
US12129304B2 (en) 2024-10-29
WO2019017499A2 (en) 2019-01-24
MX419643B (es) 2025-01-14
BR112020007731A2 (pt) 2020-10-20

Similar Documents

Publication Publication Date Title
US20250026847A1 (en) Treatment of cd20-positive b-cell lymphoma with obinutuzumab
JP2003528155A (ja) Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法
US20230270785A1 (en) Methods of administering chimeric antigen receptor immunotherapy
KR20230069181A (ko) 암 치료를 위한 방법, 요법 및 용도
WO2018015880A1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
WO2021053490A1 (en) Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
TW202131948A (zh) 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
JP2024001191A (ja) 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法
US20240226168A1 (en) Engineered nk cells and uses thereof
CN119546330A (zh) 用抑制半乳糖凝集素-9的抗体治疗血液恶性肿瘤
CN117769435A (zh) 通过施用抗cd127剂治疗cd127阳性癌症的方法
JP2024519449A (ja) がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用
HK40031517A (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
CN120093930A (zh) 用于胆管癌免疫治疗的组合物及其应用
CN120302979A (zh) 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
US20220339174A1 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
CN121003696A (zh) 一种靶向b细胞和软骨细胞衰老的骨关节炎治疗药物
CN118251234A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
Ribas et al. Overcoming PD-1 Blockade Resistance With CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients With Metastatic Melanoma (125/165 characters [incl spaces])